This ASX fund manager is predicting big things for biotech shares

This ASX fund manager is bullish on biotech shares…

medical imaging doctor amid images of human brains

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Platinum Asset Management Ltd (ASX: PTM) has long been one of the most followed funds management businesses on the ASX. Platinum was founded by the legendary ASX investor Kerr Neilson in the 1990s.

Ever since, the company has been a beacon of value investing on the ASX, even after Neilson's departure in 2018. Now, Platinum is headed by its co-founder and Neilson protege Andrew Clifford.

Clifford recently sat down with Livewire for an interview. It makes for some interesting reading.

Discussing both Platinum's history, and its prediction for the winning investing themes of the future, Clifford shared three insights.

Firstly, he sees a very bright and potentially lucrative shift towards the widespread adoption of electric vehicles. Platinum identifies the Korean company LG Chem as a major play in this space. Mr Clifford calls the company "one of the world's leading suppliers of batteries".

Secondly, Clifford identifies an opportunity in the search for replacements for single-use plastics. Pointing to Finnish forestry company UPM Kymmene Oy, he says he is excited about this company's plans to turn timber products into bio-plastics.

Biotech shares for the future

But, thirdly, Clifford is looking to the biotech space for potential future gains. He predicts biotech will "kickstart a revolution in healthcare. Not only in the way we define and treat diseases but also in the way we manufacture products":

The speed at which we're coming up with potential solutions in the biotech world — whether it's gene editing or mRNA — there are vast amounts of development in different areas of the sector that I think will transform the healthcare landscape…

The great lesson of the last year was obviously the way that mRNA technology could be used to create vaccines. We had investments in both BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ: MRNA) well ahead of COVID-19 and certainly stepped those up because we knew there would be an opportunity.

Clifford told Livewire that Dr Bianca Ogden, Platinum's International Health Care fund manager, frequently points out how "molecular biology and computer science are converging" with Artificial Intelligence (AI).

In the report, Clifford said Odgen "believes that in the next 10 years we will start defining neurological disorders by their molecular profile akin to what we do in oncology".

Exciting stuff.

The Motley Fool recently looked at some of the ASX's best-performing biotech shares over the 2021 financial year so make sure to check those out next.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Moderna Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

two men smiling with a laptop in front of them, symbolising a rising share price.
Broker Notes

These ASX 200 shares could rise 25% to 60%

Analysts think these shares are top buys and could rise materially.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finished the trading week on a sour note today.

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors are sending these four ASX 200 stocks soaring this week. But why?

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

Bell Potter says this growing ASX 200 stock can rise over 40%

Big returns could be on the cards for buyers of this stock.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A couple makes silly chip moustache faces and take a selfie on their phone.
Share Market News

Which delivered superior returns in FY25: CSL, A2 Milk, or Telstra shares?

We review the share price growth and dividend income delivered to investors in FY25.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Why IGO, Johns Lyng, Lynas, and Web Travel shares are pushing higher today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Imricor, Ora Banda, Ventia, and Vulcan shares are dropping today

These shares are ending the week in the red. But why?

Read more »